

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ni et al.

Serial No.: 09/512,366

Filed: February 23, 2000

Title: Human Tumor Necrosis Factor Receptor-Like Proteins TR11, TR11SV1 and TR11SV2

Group Art Unit: 1646

Examiner: Not assigned

Attorney Docket No.: PF396P1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-AI listed on the attached revised Form PTO/SB/08. Copies of references AA-AI are enclosed.

Reference AC was cited in an International Search Report (AI) dated July 31, 2000 issued in a foreign counterpart of the instant application.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to:

(a) SEQ ID NO:947 in copending U.S. Patent Application Serial No. 09/078,614; and

(b) SEQ ID NO:124 in copending U.S. Patent Application Serial No.

08/985,366.

Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is being filed before the mailing date of a first Office action on the merits in the instant application, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted

Date: October 31, 2000


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

Enclosures

GP 1646
RECEIVED
NOV 02 2000
TECH CENTER 1600/2300

#5/TOP
V/cont